Enhanced anticancer effects of a methylation inhibitor by inhibiting a novel DNMT1 target, CEP 131, in cervical cancer

Dong Hyun Kim, Hye Min Kim, Pham Thi Thu Huong, Ho Jin Han, Joonsung Hwang, Hyunjoo Cha-Molstad, Kyung Ho Lee, In Ja Ryoo, Kyoon Eon Kim, Yang Hoon Huh, Jong Seog Ahn, Yong Tae Kwon, Nak Kyun Soung, Bo Yeon Kim

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Methylation is a primary epigenetic mechanism regulating gene expression. 5-aza-2'-deoxycytidine is an FDA-approved drug prescribed for treatment of cancer by inhibiting DNA-Methyl-Transferase 1 (DNMT1). Results of this study suggest that prolonged treatment with 5-aza-2'-deoxycytidine could induce centrosome abnormalities in cancer cells and that CEP131, a centrosome protein, is regulated by DNMT1. Interestingly, cancer cell growth was attenuated in vitro and in vivo by inhibiting the expression of Cep131. Finally, Cep131-deficient cells were more sensitive to treatment with DNMT1 inhibitors. These findings suggest that Cep131 is a potential novel anti-cancer target. Agents that can inhibit this protein may be useful alone or in combination with DNMT1 inhibitors to treat cancer.

Original languageEnglish
Pages (from-to)342-347
Number of pages6
JournalBMB Reports
Volume52
Issue number5
DOIs
StatePublished - 2019

Keywords

  • Anti-cancer
  • CEP131
  • Centrosome
  • DNMT1

Fingerprint Dive into the research topics of 'Enhanced anticancer effects of a methylation inhibitor by inhibiting a novel DNMT1 target, CEP 131, in cervical cancer'. Together they form a unique fingerprint.

  • Cite this

    Kim, D. H., Kim, H. M., Huong, P. T. T., Han, H. J., Hwang, J., Cha-Molstad, H., Lee, K. H., Ryoo, I. J., Kim, K. E., Huh, Y. H., Ahn, J. S., Kwon, Y. T., Soung, N. K., & Kim, B. Y. (2019). Enhanced anticancer effects of a methylation inhibitor by inhibiting a novel DNMT1 target, CEP 131, in cervical cancer. BMB Reports, 52(5), 342-347. https://doi.org/10.5483/BMBRep.2019.52.5.055